OncoCyte Corporation
OncoCyte Corporation, a leading innovator in the field of cancer diagnostics, is headquartered in the United States. Founded in 2014, the company has rapidly established itself within the oncology industry, focusing on the development of advanced diagnostic tests that enhance early detection and treatment of cancer. With a strong emphasis on precision medicine, OncoCyte's core products include proprietary assays designed to identify specific cancer types, which are distinguished by their unique methodologies and high accuracy rates. The company has achieved significant milestones, including partnerships with major healthcare institutions, positioning itself as a trusted name in cancer diagnostics. OncoCyte continues to expand its operational reach, aiming to improve patient outcomes through innovative solutions in cancer care, thereby solidifying its market position as a frontrunner in the diagnostic landscape.
DitchCarbon Score
How does OncoCyte Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
OncoCyte Corporation's score of 17 is lower than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
OncoCyte Corporation's reported carbon emissions
OncoCyte Corporation, headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that OncoCyte may not have established formal commitments to reduce its carbon footprint or engage in industry-standard climate initiatives at this time. As the company operates within the biotechnology sector, it is essential for them to consider implementing robust climate strategies to align with growing industry expectations for sustainability and emissions reduction.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
OncoCyte Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
